Market capitalization | €32.23b |
Enterprise Value | €34.84b |
P/E (TTM) P/E ratio | 134.41 |
EV/FCF (TTM) EV/FCF | 70.25 |
EV/Sales (TTM) EV/Sales | 6.39 |
P/S ratio (TTM) P/S ratio | 5.91 |
P/B ratio (TTM) P/B ratio | 3.60 |
Dividend yield | 0.80% |
Last dividend (FY24) | €1.36 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
16 Analysts have issued a UCB forecast:
16 Analysts have issued a UCB forecast:
Jun '24 |
+/-
%
|
||
Revenue | 5,454 5,454 |
5%
5%
|
|
Gross Profit | 3,488 3,488 |
4%
4%
|
|
EBITDA | 1,198 1,198 |
3%
3%
|
EBIT (Operating Income) EBIT | 504 504 |
16%
16%
|
Net Profit | 240 240 |
27%
27%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
Head office | Belgium |
CEO | Jean-Christophe Tellier |
Employees | 9,083 |
Founded | 1925 |
Website | www.ucb.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.